SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (3235)2/9/2021 2:26:43 PM
From: Miljenko Zuanic  Respond to of 3557
 
At least it is tide to stock performance, and not option trading plan...that benefit who???
"...$196.5 million each.
On the absolute high end — 140% share growth over five years at a 19.2% annual rate — both Schleifer and Yancopoulos would be due a whopping $713.3 million."